Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Receivables - Other (2019 - 2021)

Keros Therapeutics filings provide 3 years of Receivables - Other readings, the most recent being $100000.0 for Q2 2021.

  • On a quarterly basis, Receivables - Other changed N/A to $100000.0 in Q2 2021 year-over-year; TTM through Jun 2021 was $100000.0, a N/A change, with the full-year FY2019 number at $900000.0, changed N/A from a year prior.
  • Receivables - Other hit $100000.0 in Q2 2021 for Keros Therapeutics, down from $805000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $900000.0 in Q4 2019 to a low of $100000.0 in Q2 2021.
  • Median Receivables - Other over the past 3 years was $805000.0 (2020), compared with a mean of $601666.7.